Transcriptome analysis reveals the essential role of NK2 homeobox 1/thyroid transcription factor 1 (NKX2-1/TTF-1) in gastric adenocarcinoma of fundic-gland type.
AGS cell transfection
Gastric carcinoma of fundic gland
Immunohistochemistry
NKX2-1/TTF-1
Transcriptome analysis
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
05
03
2022
accepted:
17
08
2022
pubmed:
13
9
2022
medline:
7
1
2023
entrez:
12
9
2022
Statut:
ppublish
Résumé
Gastric adenocarcinoma of fundic-gland type (GA-FG) is a gastric malignancy with little relation to Helicobacter pylori. Clinical characteristics of GA-FG have been established, but molecular mechanisms leading to tumorigenesis have not yet been elucidated. We subjected three GA-FG tumors-normal mucosa pairs to microarray analysis. Network analysis was performed for the top 30 up-regulated gene transcripts, followed by immunohistochemical staining to confirm the gene expression analysis results. AGS and NUGC4 cells were transfected with the gene-encoding NK2 homeobox 1/thyroid transcription factor 1 (NKX2-1/TTF-1) to evaluate transcriptional changes in its target genes. Comprehensive gene expression analysis identified 1410 up-regulated and 1395 down-regulated gene probes with ≥ two-fold difference in expression. Among the top 30 up-regulated genes in GA-FG, we identified transcription factor NKX2-1/TTF-1, a master regulator of lung/thyroid differentiation, together with surfactant protein B (SFTPB), SFTPC, and secretoglobin family 3A member 2(SCGB3A2), which are regulated by NKX2-1/TTF-1. Immunohistochemical analysis of 16 GA-FG specimens demonstrated significantly higher NKX2-1/TTF-1 and SFTPB levels, as compared to that in adjacent normal mucosa (P < 0.05), while SCGB3A2 levels did not differ (P = 0.341). Transduction of NKX2-1/TTF-1 into AGS and NUGC4 cells induced transactivation of SFTPB and SFTPC, indicating that NKX2-1/TTF-1 can function as normally in gastric cells as it can in the lung cells. Our first transcriptome analysis of GA-FG indicates significant expression of NKX2-1/TTF1 in GA-FG. Immunohistochemistry and cell biology show ectopic expression and normal transactivation ability of NKX2-1/TTF-1, suggesting that it plays an essential role in GA-FG development.
Sections du résumé
BACKGROUND
Gastric adenocarcinoma of fundic-gland type (GA-FG) is a gastric malignancy with little relation to Helicobacter pylori. Clinical characteristics of GA-FG have been established, but molecular mechanisms leading to tumorigenesis have not yet been elucidated.
METHODS
We subjected three GA-FG tumors-normal mucosa pairs to microarray analysis. Network analysis was performed for the top 30 up-regulated gene transcripts, followed by immunohistochemical staining to confirm the gene expression analysis results. AGS and NUGC4 cells were transfected with the gene-encoding NK2 homeobox 1/thyroid transcription factor 1 (NKX2-1/TTF-1) to evaluate transcriptional changes in its target genes.
RESULTS
Comprehensive gene expression analysis identified 1410 up-regulated and 1395 down-regulated gene probes with ≥ two-fold difference in expression. Among the top 30 up-regulated genes in GA-FG, we identified transcription factor NKX2-1/TTF-1, a master regulator of lung/thyroid differentiation, together with surfactant protein B (SFTPB), SFTPC, and secretoglobin family 3A member 2(SCGB3A2), which are regulated by NKX2-1/TTF-1. Immunohistochemical analysis of 16 GA-FG specimens demonstrated significantly higher NKX2-1/TTF-1 and SFTPB levels, as compared to that in adjacent normal mucosa (P < 0.05), while SCGB3A2 levels did not differ (P = 0.341). Transduction of NKX2-1/TTF-1 into AGS and NUGC4 cells induced transactivation of SFTPB and SFTPC, indicating that NKX2-1/TTF-1 can function as normally in gastric cells as it can in the lung cells.
CONCLUSIONS
Our first transcriptome analysis of GA-FG indicates significant expression of NKX2-1/TTF1 in GA-FG. Immunohistochemistry and cell biology show ectopic expression and normal transactivation ability of NKX2-1/TTF-1, suggesting that it plays an essential role in GA-FG development.
Identifiants
pubmed: 36094595
doi: 10.1007/s10120-022-01334-5
pii: 10.1007/s10120-022-01334-5
doi:
Substances chimiques
Thyroid Nuclear Factor 1
0
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
44-54Subventions
Organisme : Japan Society for the Promotion of Science
ID : 21K15940
Organisme : Japan Society for the Promotion of Science
ID : 20K16952
Commentaires et corrections
Type : CommentOn
Informations de copyright
© 2022. The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009;10(4):321–2.
doi: 10.1016/S1470-2045(09)70096-8
Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.
Inoue M. Changing epidemiology of Helicobacter pylori in Japan. Gastric Cancer. 2017;20(Suppl 1):3–7.
doi: 10.1007/s10120-016-0658-5
Wang C, Nishiyama T, Kikuchi S, Inoue M, Sawada N, Tsugane S, et al. Changing trends in the prevalence of H pylori infection in Japan (1908–2003): a systematic review and meta-regression analysis of 170,752 individuals. Sci Rep. 2017;7(1):15491.
doi: 10.1038/s41598-017-15490-7
Tsukamoto T, Yokoi T, Maruta S, Kitamura M, Yamamoto T, Ban H, et al. Gastric adenocarcinoma with chief cell differentiation. Pathol Int. 2007;57(8):517–22.
doi: 10.1111/j.1440-1827.2007.02134.x
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019;76(2):182–8. https://doi.org/10.1111/his.13975 .
doi: 10.1111/his.13975
Park ES, Kim YE, Park CK, Yao T, Kushima R, Kim KM. Gastric adenocarcinoma of fundic gland type: report of three cases. Korean J Pathol. 2012;46(3):287–91.
doi: 10.4132/KoreanJPathol.2012.46.3.287
Hidaka Y, Mitomi H, Saito T, Takahashi M, Lee SY, Matsumoto K, et al. Alteration in the Wnt/β-catenin signaling pathway in gastric neoplasias of fundic gland (chief cell predominant) type. Hum Pathol. 2013;44(11):2438–48.
doi: 10.1016/j.humpath.2013.06.002
Miyazawa M, Matsuda M, Yano M, Hara Y, Arihara F, Horita Y, et al. Gastric adenocarcinoma of fundic gland type: Five cases treated with endoscopic resection. World J Gastroenterol. 2015;21(26):8208–14.
doi: 10.3748/wjg.v21.i26.8208
Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–9.
doi: 10.1056/NEJMoa001999
Benedict MA, Lauwers GY, Jain D. Gastric Adenocarcinoma of the fundic gland type: update and literature review. Am J Clin Pathol. 2018;149(6):461–73.
doi: 10.1093/ajcp/aqy019
Chiba T, Kato K, Masuda T, Ohara S, Iwama N, Shimada T, et al. Clinicopathological features of gastric adenocarcinoma of the fundic gland (chief cell predominant type) by retrospective and prospective analyses of endoscopic findings. Dig Endosc. 2016;28(7):722–30.
doi: 10.1111/den.12676
Ueyama H, Yao T, Nakashima Y, Hirakawa K, Oshiro Y, Hirahashi M, et al. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol. 2010;34(5):609–19.
doi: 10.1097/PAS.0b013e3181d94d53
Kushima R, Sekine S, Matsubara A, Taniguchi H, Ikegami M, Tsuda H. Gastric adenocarcinoma of the fundic gland type shares common genetic and phenotypic features with pyloric gland adenoma. Pathol Int. 2013;63(6):318–25.
doi: 10.1111/pin.12070
Tohda G, Osawa T, Asada Y, Dochin M, Terahata S. Gastric adenocarcinoma of fundic gland type: Endoscopic and clinicopathological features. World J Gastrointest Endosc. 2016;8(4):244–51.
doi: 10.4253/wjge.v8.i4.244
Nomura R, Saito T, Mitomi H, Hidaka Y, Lee SY, Watanabe S, et al. GNAS mutation as an alternative mechanism of activation of the Wnt/β-catenin signaling pathway in gastric adenocarcinoma of the fundic gland type. Hum Pathol. 2014;45(12):2488–96.
doi: 10.1016/j.humpath.2014.08.016
Ushiku T, Kunita A, Kuroda R, Shinozaki-Ushiku A, Yamazawa S, Tsuji Y, et al. Oxyntic gland neoplasm of the stomach: expanding the spectrum and proposal of terminology. Mod Pathol. 2020;33(2):206–16.
doi: 10.1038/s41379-019-0338-1
Kawasaki K, Kurahara K, Oshiro Y, Matsumoto T. Depressed gastric adenocarcinoma of the fundic gland type. Intern Med. 2016;55(5):543–4.
doi: 10.2169/internalmedicine.55.5706
Sato Y, Fujino T, Kasagawa A, Morita R, Ozawa SI, Matsuo Y, et al. Twelve-year natural history of a gastric adenocarcinoma of fundic gland type. Clin J Gastroenterol. 2016;9(6):345–51.
doi: 10.1007/s12328-016-0680-5
Kato M, Uraoka T, Isobe Y, Abe K, Hirata T, Takada Y, et al. A case of gastric adenocarcinoma of fundic gland type resected by combination of laparoscopic and endoscopic approaches to neoplasia with non-exposure technique (CLEAN-NET). Clin J Gastroenterol. 2015;8(6):393–9.
doi: 10.1007/s12328-015-0619-2
Li C, Wu X, Yang S, Yang X, Yao J, Zheng H. Gastric adenocarcinoma of the fundic gland type: clinicopathological features of eight patients treated with endoscopic submucosal dissection. Diagn Pathol. 2020;15(1):131.
doi: 10.1186/s13000-020-01047-2
Kurihara N, Kubota T, Otani Y, Ohgami M, Kumai K, Sugiura H, et al. Lymph node metastasis of early gastric cancer with submucosal invasion. Br J Surg. 1998;85(6):835–9.
doi: 10.1046/j.1365-2168.1998.00743.x
Abe T, Nagai T, Fukunaga J, Okawara H, Nakashima H, Syutou M, et al. Long-term follow-up of gastric adenocarcinoma with chief cell differentiation using upper gastrointestinal tract endoscopy. Intern Med. 2013;52(14):1585–8.
doi: 10.2169/internalmedicine.52.0361
Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol. 2001;158(3):1005–10.
doi: 10.1016/S0002-9440(10)64047-3
Sekine S, Shibata T, Yamauchi Y, Nakanishi Y, Shimoda T, Sakamoto M, et al. Beta-catenin mutations in sporadic fundic gland polyps. Virchows Arch. 2002;440(4):381–6.
doi: 10.1007/s004280100527
Sakaguchi Y, Yamamichi N, Tomida S, Takeuchi C, Kageyama-Yahara N, Takahashi Y, et al. Identification of marker genes and pathways specific to precancerous duodenal adenomas and early stage adenocarcinomas. J Gastroenterol. 2019;54(2):131–40.
doi: 10.1007/s00535-018-1489-4
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676–82.
doi: 10.1038/nmeth.2019
Landini G, Martinelli G, Piccinini F. Colour deconvolution: stain unmixing in histological imaging. Bioinformatics. 2021;37(10):1485–7.
doi: 10.1093/bioinformatics/btaa847
Griesing S, Kajino T, Tai MC, Liu Z, Nakatochi M, Shimada Y, et al. Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells. Cancer Sci. 2017;108(7):1394–404.
doi: 10.1111/cas.13271
Yamamichi N, Yamamichi-Nishina M, Mizutani T, Watanabe H, Minoguchi S, Kobayashi N, et al. The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene. 2005;24(35):5471–81.
doi: 10.1038/sj.onc.1208716
Takemoto T. Chronic gastritis. Jpn J Med. 1985;24(3):276–82.
doi: 10.2169/internalmedicine1962.24.276
Lindskog C, Fagerberg L, Hallström B, Edlund K, Hellwig B, Rahnenführer J, et al. The lung-specific proteome defined by integration of transcriptomics and antibody-based profiling. FASEB J. 2014;28(12):5184–96.
doi: 10.1096/fj.14-254862
Niimi T, Keck-Waggoner CL, Popescu NC, Zhou Y, Levitt RC, Kimura S. UGRP1, a uteroglobin/Clara cell secretory protein-related protein, is a novel lung-enriched downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor. Mol Endocrinol. 2001;5(11):2021–36.
doi: 10.1210/mend.15.11.0728
Kim SK, Seok H, Park HJ, Han K, Kang SW, Ban JY, et al. Association between Secretoglobin family 3A member 2 (SCGB3A2) gene polymorphisms and asthma in a Korean Population. Med Sci Monit. 2017;23:1880–5.
doi: 10.12659/MSM.903983
Tanaka H, Yanagisawa K, Shinjo K, Taguchi A, Maeno K, Tomida S, et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res. 2007;67(13):6007–11.
doi: 10.1158/0008-5472.CAN-06-4774
Yamaguchi T, Hosono Y, Yanagisawa K, Takahashi T. NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression. Cancer Cell. 2013;23(6):718–23.
doi: 10.1016/j.ccr.2013.04.002
Stanfel MN, Moses KA, Schwartz RJ, Zimmer WE. Regulation of organ development by the NKX-homeodomain factors: an NKX code. Cell Mol Biol (Noisy-le-grand) 2005;Suppl 51:OL785–99.
Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci (Lond). 2009;116(1):27–35.
doi: 10.1042/CS20080068
Minoo P, Hu L, Xing Y, Zhu NL, Chen H, Li M, et al. Physical and functional interactions between homeodomain NKX2.1 and winged helix/forkhead FOXA1 in lung epithelial cells. Mol Cell Biol. 2007;27(6):2155–65.
doi: 10.1128/MCB.01133-06
Kurotani R, Tomita T, Yang Q, Carlson BA, Chen C, Kimura S. Role of secretoglobin 3A2 in lung development. Am J Respir Crit Care Med. 2008;178(4):389–98.
doi: 10.1164/rccm.200707-1104OC
Zamecnik J, Kodet R. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases. Virchows Arch. 2002;440(4):353–61.
doi: 10.1007/s00428-001-0552-2
Moldvay J, Jackel M, Bogos K, Soltész I, Agócs L, Kovács G, et al. The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res. 2004;10(2):85–8.
doi: 10.1007/BF02893461
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.
doi: 10.1097/JTO.0b013e318206a221
Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, et al. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012;118(11):2889–99.
doi: 10.1002/cncr.26584
Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, et al. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 2011;17(8):2434–43.
doi: 10.1158/1078-0432.CCR-10-1412
Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol. 2009;27(2):271–8.
doi: 10.1200/JCO.2008.17.0043
Berghmans T, Paesmans M, Mascaux C, Martin B, Meert AP, Haller A, et al. Thyroid transcription factor 1–a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol. 2006;17(11):1673–6.
doi: 10.1093/annonc/mdl287
Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature. 2011;473(7345):101–4.
doi: 10.1038/nature09881
Chiurillo MA. Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review. World J Exp Med. 2015;5(2):84–102.
doi: 10.5493/wjem.v5.i2.84